Abstract:Hazel M O'Sullivan, 1 Andrew Feber, 2 Sanjay Popat 1– 3 1 Lung Unit, Royal Marsden NHS Foundation Trust, London, UK; 2 The Institute of Cancer Research, London, UK; 3 National Heart and Lung Institute, Imperial College London, London, UK Correspondence: Sanjay Popat, The Lung Unit, The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom, Tel +442073528171, Email Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it is clinically or radiologically evident. Minimal residual disease (MRD) is an advancing area in the management of radically treated solid tumors. Which MRD assay is optimum and when it should be used is still not defined. Whilst promising, the clinical utility of this technology to guide patient care is still investigational in non-small cell lung cancer (NSCLC) and has not entered routine care. Once technically and clinically optimized, MRD may be utilized to personalize adjuvant therapy, detect disease relapse earlier and improve cure rates. In this review, we discuss the current status of MRD monitoring in NSCLC by summarizing frequently used MRD assays and their associated evidence in NSCLC. We discuss the potential applications of these technologies and the challenge of demonstrating MRD clinical utility in trials. Keywords: MRD, ctDNA, NSCLC, adjuvant therapy, minimal residual disease, non-small cell lung cancer, circulating tumor DNA Cell-free DNA (cfDNA) refers to fragments of DNA released into the circulation by endothelial cells and white blood cells by active release or passively through apoptosis and necrosis. 1,2 The fraction of cfDNA that originates from tumor is known as circulating tumor DNA (ctDNA). In 2016 the first commercial ctDNA test was approved for use in non-small cell lung cancer (NSCLC); the cobas EGFR mutation test, a real-time polymerase chain reaction (PCR) companion diagnostic test, was designed to identify advanced stage NSCLC patients eligible for treatment with erlotinib. 3 Since then, ctDNA use has exponentially increased in the management of advanced NSCLC. In the advanced setting, evidence supports the use of multigene next generation sequencing (NGS) ctDNA assays upfront, concurrently, or sequentially with tissue biopsies to genotype newly diagnosed patients. ctDNA analysis is also advantageous throughout treatment. In multiple solid tumors, including NSCLC, a "molecular response" has been shown to correlate with superior clinical outcomes. This refers to a reduction in ctDNA variant allele frequency (VAF) following the initiation of treatment and may identify a response to therapy earlier than imaging. 4–13 In oncogene-addicted NSCLC, ctDNA analysis is frequently used at the point of disease progression to potentially identify any resistance mechanisms to aid next-line treatment selection. 14,15 Furthermore, ctDNA VAF is prognostic in early NSCLC, stage I patients with preoperatively detectable ctDNA have an increased risk of recurrence compared to those with stage I disease with no ctDNA identified prior to resection. 16 This suggests the presence of detectable ctDNA in such patients may represent the existence of occult micro metastatic disease at the time of surgery. ctDNA can also be used in the surveillance of radically treated patients to detect minimal residual disease (MRD), i.e., molecular evidence of cancer soon after curative treatment. In contrast to the management of a metastatic patient, where ctDNA assessment is necessary to identify specific targetable alterations to guide therapy, in the radical setting it is the presence of ctDNA in any quantity, not quality, which is important. However, MRD identification is challenging. Assays need to be sufficiently sensitive to detect the small fraction of tumor-derived ctDNA among the abundant cfDNA from normal cells, risking false negative and false positive results. Moreover, even if MRD can be reliably assessed, it's assessment is not currently recommended by international guidelines as the clinical utility is yet to be sufficiently established, randomized trials are ongoing to define this. Once optimized, MRD status may be used to personalize adjuvant therapy, detect disease relapse earlier, and improve cure rates. In this review, we summarize frequently used MRD assays and their associated observational evidence in NSCLC. We discuss the potential applications of these technologies and the challenge of demonstrating MRD clinical utility in trials. Assays used in the detection of MRD can be divided into the tumor genotype informed and genotype uninformed (Figure 1). The tumor informed approach involves prior knowledge of a tumor genotype, via analysis of a tumor specimen and/or preoperative cfDNA, to develop and customize a panel of mutatio -Abstract Truncated-

High sensitivity circulating tumor-DNA assays in Renal Cell Carcinoma – Are we there yet?

Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors

Tumor characteristics associated with detectable circulating tumor DNA preoperatively in patients with renal masses suspicious for RCC.

Circulating tumor DNA in the surveillance of patients with oligometastatic renal cell carcinoma treated with stereotactic ablative radiation.

Longitudinal and Personalized Detection of Circulating Tumor DNA (ctdna) for Monitoring Efficacy of Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma (HCC).

Comparison of primary versus metastatic tumor tissue sources when designing panels for whole genome–based tumor-informed ctDNA assays in clear cell renal cell carcinoma.

Circulating Tumor Cells as Biomarkers for Renal Cell Carcinoma: Ready for Prime Time?

Utility of circulating tumor DNA (ctDNA) for the detection of minimal residual disease (MRD) after curative-intent therapy for patients with localized pancreatic adenocarcinoma (PDAC): A single institution series and meta-analysis.

Next-generation MRD assays: do we have the tools to evaluate them properly?

Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors

Characterization of molecular response and progression in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors using a high-sensitivity tumor-informed assay.

Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in invasive bladder cancer in clinical practice.

KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer – an observational trial. Study protocol

Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application

2262P Baseline-informed Versus Tumor-Agnostic Minimal Residual Disease (MRD) Concordance Study in Patients with HER2+ Gastroesophageal Adenocarcinoma Patients

Abstract 2429: Longitudinal ctDNA monitoring using a high sensitivity tumor-informed assay in patients with metastatic HR+/HER2− breast cancer receiving endocrine therapy and CDK4/6 inhibitors

Exploring the Characteristics of Circulating Tumor DNA in Pt1a Clear Cell Renal Cell Carcinoma: A Pilot Study

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications

Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.

Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?